Need Help With This Product?
Our specialists are here to help you find the best product for your application.
iCell Cardiac Progenitor Cells Kit, 01279
Advance cardiovascular research with iCell® Cardiac Progenitor Cells, translational in vitro models derived from human induced pluripotent stem cells (iPSCs).
- Effortless consistency Ready to use from thaw, iCell Cardiac Progenitor Cells offer high purity and deliver reproducible results.
- Native characteristics With a KDR+/PDGFR-α+/c-Kit– profile, these cardiac progenitor cells (CPCs) offer a highly human-relevant model.
- Therapeutic relevance iCell Cardiac Progenitor Cells are proliferative and capable of differentiating into cardiomyocytes.
- Versatile utility From cardiac development and regeneration to toxicity screening, these cells enable diverse research.
- Scalable screening These CPCs support high-throughput target- and phenotype-based screens for drug discovery and toxicity research.
$1,395.00
Products
Kits
- Cryopreserved iCell Cardiac Progenitor Cells, 01279
- User’s Guide
- Additional reagents required. Please see User’s Guide.
genetic status
quantity (Cells Per Vials)
catalog #
Catalog #: R1093
iCell Cardiac Progenitor Cells Kit, 01279
From
$1,395.00
Product Overview
Cardiac progenitor cells (CPCs) are able to proliferate and have the capacity to differentiate into cardiomyocytes. Thus, these cells are attractive targets in drug development applications for regenerative medicine programs focused on developing myocardial infarction and congestive heart failure treatments. They are also ideal for identifying and helping to avoid drug-mediated cardiac developmental toxicity problems across multiple programs, an application for which scientists require consistent and dependable access to human CPCs.
Derived from human iPS cells, FCDI's iCell® Cardiac Progenitor Cells provide a robust, reproducible, and relevant source of cells to advance drug development and cardiac regenerative medicine programs. Benefits include:
- KDR+/PDGFR-α+/c-kit– human CPC marker profile
- bFGF-mediated proliferation
- Wnt inhibitor-mediated differentiation into cTNT+ cardiomyocytes
- High-throughput target and phenotypic-based screen compatibility
Components:
Catalog #R1093
iCell Cardiac Progenitor Cells Kit, 01279, 1 Vial: ≥ 5 x 10^6 cells/vial
- Cryopreserved iCell Cardiac Progenitor Cells, 01279
- User’s Guide
- Additional reagents required. Please see User’s Guide.
Donor Background
Sex:
MaleRace:
CaucasianCell Type:
Cardiac Progenitor CellsSource Line:
01279Modeled Disease Phenotype:
Apparently Healthy NormalDonor Status:
Apparently Healthy NormalTissue Source:
BloodAge At Sampling:
50-59Engineered Line:
NoDisease Status:
Apparently Healthy Normal (AHN)Our regular business hours are 9:00am to 5:00pm Central Time (USA)
Need Help With This Product?
Our specialists are here to help you find the best product for your application.
Our regular business hours are 9:00am to 5:00pm Central Time (USA)
Technical Docs
PROTOCOLS
Application Protocols
Modeling Cardiomyocyte Differentiation: Wnt- and Activin/TGFβ-inhibitor Induction with Flow Cytometry Analysis
Application Protocols
Modeling Cardiac Proliferation: bFGF Induction with High Content Analysis
USER DOCS
User's Guides
iCell Cardiac Progenitor Cells User's Guide
Biosafety Document
iCell Cardiac Progenitor Cells Biosafety Document
Safety Data Sheet
iCell Cell-Based Products Safety Data Sheet - Asia
Safety Data Sheet
iCell Cell-Based Products Safety Data Sheet
Performance Data
Differentiation into Cardiac Cells
iCell Cardiac Progenitor Cells differentiated into cardiomyocytes as indicated by the increase in cTNT expression in the induced condition. Acquisition and analysis were performed using a BD Accuri C6 Flow Cytometer (BD Biosciences). iCell Cardiac Progenitor Cells were plated in the presence of XAV939/SB431542 for 2 days and assayed on day 8 post-plating
Figure 1: Flow Cytometry Detection of cTNT Expression in Cardiomyocytes Differentiated from XAV939/SB431542-induced iCell Cardiac Progenitor Cells
Figure 2: Detection and Quantification of bFGF-induced Cardiac Proliferation by High Content Analysis
Induction of Cell Proliferation
In this representative experiment, cell proliferation of iCell Cardiac Progenitor Cells was induced as indicated by the increase in the Hoechst 33342+ /NKX2.5+ /cTNT– cell population in the treatment condition. Acquisition and analysis were performed using the ImageXpress Micro System and MetaXpress Software. iCell Cardiac Progenitor Cells were plated in the presence of bFGF for 2 days and assayed on day 2 post plating.
Product Highlights
iCell Cardiac Progenitor Cells
- iCell Cardiac Progenitor Cells represent an optimal in vitro test system for interrogating human cardiac regenerative biology due to their human origin, high purity, functional relevance, and ease of use.
- Suitable for inducing proliferation with basic fibroblast growth factor (bFGF). A detailed protocol is available.
- Also well suited for induction of proliferation with Wnt inhibitor XAV939 and activin/TGFβ inhibitor SB431542 as assessed by the expression of cardiac troponin T (cTNT) using flow cytometry analysis. A detailed protocol is available.
Publications
miRNAs in Extracellular Vesicles from iPS-Derived Cardiac Progenitor Cells Effectively Reduce Fibrosis and Promote Angiogenesis in Infarcted Heart Xuan W, Wang L, Xu M, Weintraub NL, Ashraf M. (2019) Stem Cells International Volume 2019, Article ID 3726392. (2019)